Quantcast

Latest Onyx Pharmaceuticals Inc. Stories

2014-09-10 12:28:52

-Dr. Cagnoni Joins Non-Profit Organization Focused on Fostering Innovation and Collaboration to Strengthen the Bay Area BioEconomy- SAN FRANCISCO, Sept. 10, 2014 /PRNewswire/ -- The Bay Area BioEconomy Initiative (BAB) today announced that it has named Pablo J. Cagnoni, M.D., President of Onyx Pharmaceuticals, Inc., to its Steering Committee. Onyx, an Amgen subsidiary, is engaged in the development and commercialization of innovative therapies to improve the lives of people with...

2014-08-13 16:25:38

THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Aug. 13, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that the Phase 3 clinical trial FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple Myeloma European Study) did not meet its primary endpoint of improving overall survival (OS) (HR=0.975, 95 percent CI, 0.760, 1.249). The 315-patient, open-label study evaluated single-agent Kyprolis(®) (carfilzomib) for Injection...

2014-08-04 08:27:13

Kyprolis Helped Patients Live 8.7 Months Longer Without Their Disease Worsening THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Aug. 4, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) met its...

2014-07-25 04:21:37

WHIPPANY, N.J. and SOUTH SAN FRANCISCO, Calif., July 25, 2014 /PRNewswire/ -- Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary (NASDAQ: AMGN), today announced that an investigational Phase 3 trial of NEXAVAR(®) (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS). The study, called RESILIENCE, evaluated the efficacy and safety of sorafenib in combination with capecitabine, an...

2014-05-27 16:25:23

New Data Reinforces Commitment to Personalized Medicine and Highlights Advances in Immunotherapy Platform THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., May 27, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., today announced data from several studies of both pipeline and marketed products will be presented at the 50(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 30-June 3 in Chicago. The research that will...

2014-04-23 20:23:23

WHIPPANY, N.J. and THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., April 23, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that The Lancet published online results from the Phase 3 DECISION trial which demonstrated that NEXAVAR(®) (sorafenib) tablets significantly extended the time patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is...

2014-03-11 04:21:19

WHIPPANY, N.J., THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., March 11, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a Phase 3 trial evaluating the investigational use of NEXAVAR(®) (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma (HCC), or liver cancer, who had no detectable disease after surgical resection or local ablation, did not...

2014-01-28 16:25:52

2013 GAAP EPS Were $6.64 THOUSAND OAKS, Calif., Jan. 28, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2013. Key results include: -- For the fourth quarter, total revenues increased 13 percent to $5,011 million, with product sales growing at 11 percent. Adjusted EPS grew 30 percent to $1.82, with higher revenues, the end of the Enbrel(®) (etanercept) profit share, and a lower tax rate partially...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related